TY - JOUR
T1 - Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation
AU - D’Angelo, Christopher R.
AU - Novitsky, Brianna
AU - Mee Lee, Sang
AU - Godley, Lucy A.
AU - Kline, Justin
AU - Larson, Richard A.
AU - Liu, Hongtao
AU - Odenike, Olatoyosi
AU - Stock, Wendy
AU - Bishop, Michael R.
AU - Artz, Andrew S.
N1 - Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/2/23
Y1 - 2019/2/23
N2 - Higher comorbidity by the hematopoietic cell transplantation–comorbidity index increases rates of non-relapse mortality (NRM) and impairs survival following allogeneic hematopoietic transplantation. We explored the effects of cancer as a comorbid condition prior to allogeneic transplantation. Among 356 adult transplant recipients, 54 patients (15%) had 58 comorbid cancers. Among 33 solid cancers (9%), breast (n = 12; 20%) was most common; among 26 comorbid hematologic malignancies (i.e. separate hematologic malignancy not related to primary disease) (7%), lymphoma was most common (n = 14; 24%). In unadjusted analysis, increased risks for NRM were found for cancer comorbidity (HR 2.1, p <.001), solid tumor alone (HR 2.1, p <.001), and hematologic malignancy alone (HR 1.9, p =.03). Cancer comorbidity did not impair 2-year overall survival (HR 1.33, CI 0.92–1.94). Both hematologic and solid cancers likely contribute to elevated risks of nonrelapse mortality, unrelated to recurrence of the cancer comorbidity. Further study is indicated to validate these findings.
AB - Higher comorbidity by the hematopoietic cell transplantation–comorbidity index increases rates of non-relapse mortality (NRM) and impairs survival following allogeneic hematopoietic transplantation. We explored the effects of cancer as a comorbid condition prior to allogeneic transplantation. Among 356 adult transplant recipients, 54 patients (15%) had 58 comorbid cancers. Among 33 solid cancers (9%), breast (n = 12; 20%) was most common; among 26 comorbid hematologic malignancies (i.e. separate hematologic malignancy not related to primary disease) (7%), lymphoma was most common (n = 14; 24%). In unadjusted analysis, increased risks for NRM were found for cancer comorbidity (HR 2.1, p <.001), solid tumor alone (HR 2.1, p <.001), and hematologic malignancy alone (HR 1.9, p =.03). Cancer comorbidity did not impair 2-year overall survival (HR 1.33, CI 0.92–1.94). Both hematologic and solid cancers likely contribute to elevated risks of nonrelapse mortality, unrelated to recurrence of the cancer comorbidity. Further study is indicated to validate these findings.
KW - Cancer
KW - comorbidity
KW - hematopoietic cell transplantation
KW - nonrelapse mortality
UR - http://www.scopus.com/inward/record.url?scp=85052069687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052069687&partnerID=8YFLogxK
U2 - 10.1080/10428194.2018.1493728
DO - 10.1080/10428194.2018.1493728
M3 - Article
C2 - 30070150
AN - SCOPUS:85052069687
VL - 60
SP - 629
EP - 638
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 3
ER -